<DOC>
	<DOC>NCT02043301</DOC>
	<brief_summary>This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.</brief_summary>
	<brief_title>Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Male and female subjects 18 to 65 years of age. Body Mass Index (BMI) â‰¤ 33 kg/m2, and total body weight of 60 kg to 90 kg (132 lbs to 198 lbs). Fasting LDLC must be &gt; 130 mg/dL (borderline high per NCEP ATP III criteria) at two qualifying visits: initial screening (Days 28 to 14) and Day 7. Poorly controlled type 1 or type 2 diabetes mellitus (HbA1c &gt; 9.0%). History of a cardiovascular or cerebrovascular event (eg, MI, stroke, TIA) or related procedure (eg, angioplasty) during the past year. Subjects who meet the New York Heart Association (NYHA) criteria for congestive heart failure (CHF) classes III or IV.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioavailability</keyword>
	<keyword>PF-04950615</keyword>
</DOC>